The Safety Rates Drug Report

Member Login
2004.Q1    2004.Q2    2004.Q3    2004.Q4    2005.Q1    2005.Q2    2005.Q3    2005.Q4    2006.Q1    2006.Q2    2006.Q3    2006.Q4    2007.Q1    2007.Q2    2007.Q3    2007.Q4    2008.Q1    2008.Q2    2008.Q3    2008.Q4    2009.Q1    2009.Q2    2009.Q3    2009.Q4    2010.Q1    2010.Q2    2010.Q3    2010.Q4    2011.Q1    2011.Q2    2011.Q3    2011.Q4    2012.Q1    2012.Q2    2012.Q3    2012.Q4    2013.Q1    2013.Q2    2013.Q3    2013.Q4    2014.Q1    2014.Q2    2014.Q3    2014.Q4    2015.Q1    2015.Q2    2015.Q3    2015.Q4    2016.Q1    2016.Q2    2016.Q3   

Drug     Injury     Quarter    

Drug: triamcinolone     Quarter: 2016Q3

Total Drug/Injury Combinations: 351     Number of Pages: 18

DRUGNAME PT EventCount
TRIAMCINOLONE ACETONIDE. Chorioretinopathy 3 view events
TRIAMCINOLONE ACETONIDE. Dry mouth 3 view events
TRIAMCINOLONE ACETONIDE. Pruritus 3 view events
TRIAMCINOLONE ACETONIDE. Rash 3 view events
TRIAMCINOLONE ACETONIDE. Retinal artery occlusion 3 view events
TRIAMCINOLONE Cataract 2 view events
TRIAMCINOLONE Chapped lips 2 view events
TRIAMCINOLONE Chorioretinopathy 2 view events
Triamcinolone Drug eruption 2 view events
Triamcinolone Drug hypersensitivity 2 view events
TRIAMCINOLONE Eczema 2 view events
Triamcinolone Eyelid ptosis 2 view events
Triamcinolone Hyperhidrosis 2 view events
Triamcinolone Hypoaesthesia 2 view events
TRIAMCINOLONE Lip swelling 2 view events
Triamcinolone Neuropathy peripheral 2 view events
TRIAMCINOLONE Off label use 2 view events
TRIAMCINOLONE Steroid withdrawal syndrome 2 view events
TRIAMCINOLONE ACETATE Cystoid macular oedema 2 view events
TRIAMCINOLONE ACETATE Fibrosis 2 view events

Total Drug/Injury Combinations: 351     Number of Pages: 18

NOTE: EventCount numbers on this page include duplicate entries from event reports. (e.g. One event has DrugX entered twice, which equals 2 on this page.) The "view events" page treats these duplicates as single entries. (e.g. The 2 entries of DrugX for a single event are counted as 1 instance.)